JCEM:肥胖与乳腺癌风险

2022-04-24 MedSci原创 MedSci原创

将代谢健康指标和身体成分指标与体重指数结合可以更全面地捕捉乳腺癌风险。需要进一步研究针对身体脂肪水平的干预措施,以遏制日益增加的肥胖相关癌症。

乳腺癌(BC)是全球最常见的恶性肿瘤,每年有超过230万例新诊断的病例。与此同时,肥胖的患病率正以惊人的速度上升,预计到2030年,将影响美国近50%的成年人。肥胖是绝经后激素受体阳性BC一个已知的危险因素。最近,体重增加和高体脂水平,甚至在身体质量指数(BMI)正常的个体中,已被确定为额外的BC危险因素。在全球范围内,乳腺癌的发病率与肥胖率的上升同步上升。肥胖被认为是乳腺癌发展的主要可变的危险因素;然而,这种相关性因临床病理特征而有很大差异,其潜在机制也很复杂。

近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,研究人员在Pubmed数据库种使用“肥胖”、“乳腺癌风险”、“饮食”、“运动”、“体重增加”、“体重减轻”、“脂肪组织炎症”、“冠状结构”、“免疫标记物”、“二甲双胍”、“格列净”、“SGLT-2i”和“GLP1-RA”相关术语组合搜索了文献。

研究人员合成数据后发现体重指数升高和体重增加与绝经后激素受体阳性乳腺癌风险增加有关。新出现的证据表明,任何体重的人身体成分的不良指标也会增加患乳腺癌的风险。

在机制上,包括脂肪因子平衡改变、脂肪组织功能失调、胰岛素信号失调和慢性炎症在内的各种因素都会促进乳腺癌的发生。减肥,更具体地说,通过生活方式和药物干预减少脂肪量,可以改善血清代谢和炎症标志物、性激素水平和乳房密度,这表明与降低乳腺癌风险有关。

由此可见,将代谢健康指标和身体成分指标与体重指数结合可以更全面地捕捉乳腺癌风险。需要进一步研究针对身体脂肪水平的干预措施,以遏制日益增加的肥胖相关癌症。

原始出处:

Sandra Naaman,et al.Obesity and breast cancer risk: the oncogenic implications of metabolic dysregulation.JCEM.2022.https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgac241/6572669?login=true

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1778234, encodeId=d6591e78234da, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun May 22 16:06:06 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063616, encodeId=e8d92063616cb, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jan 02 05:06:06 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062088, encodeId=d20020620886a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 11 23:06:06 CST 2023, time=2023-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770349, encodeId=27b01e703495c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Mar 19 01:06:06 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213913, encodeId=27d01213913a6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79588133126, createdName=ms1000001390073057, createdTime=Sun Apr 24 15:34:24 CST 2022, time=2022-04-24, status=1, ipAttribution=)]
    2022-05-22 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1778234, encodeId=d6591e78234da, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun May 22 16:06:06 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063616, encodeId=e8d92063616cb, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jan 02 05:06:06 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062088, encodeId=d20020620886a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 11 23:06:06 CST 2023, time=2023-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770349, encodeId=27b01e703495c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Mar 19 01:06:06 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213913, encodeId=27d01213913a6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79588133126, createdName=ms1000001390073057, createdTime=Sun Apr 24 15:34:24 CST 2022, time=2022-04-24, status=1, ipAttribution=)]
    2023-01-02 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1778234, encodeId=d6591e78234da, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun May 22 16:06:06 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063616, encodeId=e8d92063616cb, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jan 02 05:06:06 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062088, encodeId=d20020620886a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 11 23:06:06 CST 2023, time=2023-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770349, encodeId=27b01e703495c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Mar 19 01:06:06 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213913, encodeId=27d01213913a6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79588133126, createdName=ms1000001390073057, createdTime=Sun Apr 24 15:34:24 CST 2022, time=2022-04-24, status=1, ipAttribution=)]
    2023-03-11 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=1778234, encodeId=d6591e78234da, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun May 22 16:06:06 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063616, encodeId=e8d92063616cb, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jan 02 05:06:06 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062088, encodeId=d20020620886a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 11 23:06:06 CST 2023, time=2023-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770349, encodeId=27b01e703495c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Mar 19 01:06:06 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213913, encodeId=27d01213913a6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79588133126, createdName=ms1000001390073057, createdTime=Sun Apr 24 15:34:24 CST 2022, time=2022-04-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1778234, encodeId=d6591e78234da, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun May 22 16:06:06 CST 2022, time=2022-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063616, encodeId=e8d92063616cb, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Mon Jan 02 05:06:06 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062088, encodeId=d20020620886a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sat Mar 11 23:06:06 CST 2023, time=2023-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770349, encodeId=27b01e703495c, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Sun Mar 19 01:06:06 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213913, encodeId=27d01213913a6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79588133126, createdName=ms1000001390073057, createdTime=Sun Apr 24 15:34:24 CST 2022, time=2022-04-24, status=1, ipAttribution=)]
    2022-04-24 ms1000001390073057

    学习

    0

相关资讯

Lancet Oncol:曲妥珠单抗+帕妥珠单抗±紫杉醇降级治疗HER2+/HR-早期乳腺癌

曲妥珠单抗+帕妥珠单抗±紫杉醇治疗12周后获得病理完全缓解的患者可获得很好的生存率

Radiology:人工智能,为女性乳腺癌筛查“减负”!

现阶段,人工智能(AI)模型的使用可以协助临床缩短乳腺筛查的评估时间。

European Radiology:全自动乳腺超声(ABUS)成像技术在乳腺病变诊断中的应用

自动乳腺超声(ABUS)可以代替常用的手持式超声(HHUS),实现图像采集的标准化,完全覆盖整个乳腺体积,并将采集任务交给技术人员以减少人为误差。

2022CSCO:殷永梅教授:HER-2阳性乳腺癌诊疗指南3大更新要点

最新HER-2阳性乳腺癌指南!看看指南怎么说。

Nat Commun:HMMR过表达增加BRCA1相关乳腺癌患病风险

过表达HMMR可促进BRCA1相关乳腺癌的发生发展

重磅!《2022年新版乳腺癌诊疗指南》正式发布

乳腺癌是女性常见的恶性肿瘤之一,发病率位居女性恶性肿瘤的首位,严重危害妇女的身心健康。